Hypocalcémie | Clinique Omicron Québec
Obtenir un avis adapté à votre situation
Consultation en clinique ou en téléconsultation, partout au Québec.
Pathophysiology, etiologies and clinical picture
- Calcium metabolism and mechanisms of hypocalcemia : reminder of calcium regulation - see also Hypercalcemia sheet for full details : low ionized calcium → activation of parathyroid CaSR → secretion of PTH → renal effects (distal tubular calcium reabsorption + phosphaturia + stimulation of 1α-hydroxylase → calcitriol) + bone effects (osteoclastic resorption via RANK-L) + indirect intestinal effects (via calcitriol) → correction of calcemia; pathophysiological mechanisms of hypocalcemia: reduction of PTH (hypoparathyroidism) → simultaneous loss of renal calcium reabsorption + bone resorption + calcitriol production → profound hypocalcemia + hyperphosphatemia + relative hypercalciuria (kidney without PTH no longer reabsorbs filtered calcium filtered calcium) → vitamin D deficiency → reduced calcitriol production → reduced intestinal calcium absorption + reduced renal reabsorption + secondary elevation of PTH (compensatory secondary hyperparathyroidism) → elevated PTH + low 25-OHD low + calcitriol low + hypophosphatemia (PTH → phosphaturia) + acute respiratory alkalosis → pH increases → calcium-albumin binding increases → ionized calcium decreases abruptly → hypocalcemic tetany without true total hypocalcemia → hyperventilation + acute anxiety → ionized pseudo-hypocalcemia → resolution by bag breathing → hyperphosphatemia (CKD + hypoparathyroidism) → forms calcium-phosphate complexes → precipitation → reduction of ionized calcium ; calcium correction for albumin (formula identical to hypercalcemia): corrected calcium = measured calcium + 0.02 × (40 - albumin g/L) → if albuminemia = 20 g/L + measured calcium = 2.0 mmol/L → corrected calcium = 2.0 + 0.02 × 20 = 2.40 mmol/L → true normocalcemia (pseudo-hypocalcemia) → ionized calcium remains the reference in case of doubt → alkalosis → increases albumin-calcium binding → low ionized calcium despite normal total calcium → acidosis → the reverse → always interpret taking pH into account ; hungry bone syndrome: after parathyroidectomy for severe HPP or thyroid surgery with parathyroid involvement → sudden influx of calcium + phosphorus to bone (rapid remineralization post-PTH) → profound and prolonged hypocalcemia + hypophosphatemia + hypomagnesemia → Witteveen 2013 - Journal of Bone and Mineral Research: predictive factors for hungry bone syndrome: severe PPH + very high alkaline phosphatases + radiological bone LVH → massive IV calcium supplementation required + calcitriol + magnesium
- Etiologies of hypocalcemia - classification by mechanism : PTH deficiency - hypoparathyroidism: post-surgical (most frequent cause): total thyroidectomy + total parathyroidectomy + cervical lymph node emptying → involuntary lesion or removal of parathyroids → hypocalcemia in the 24-72h post-operatively → transient (6 months) in 30-40 % of cases → definitive in 1-3 % of total thyroidectomies → risk factors: bulky goiter surgery + re-operative thyroidectomy + extensive oncological surgery → autoimmune: anti-parathyroid antibodies + isolated or associated with APS-1 syndrome (autoimmune polyendocrinopathy type 1 - AIRE - hypoparathyroidism + adrenal insufficiency + mucocutaneous candidiasis) → genetic: DiGeorge syndrome (22q11 deletion.2 - thymic aplasia + congenital heart disease + hypoparathyroidism) + CaSR activating mutation (CaSR hyperactivity → constitutive PTH brake → hypocalcemia + hypercalciuria → Pollak 1994 - Nature Genetics) + PTH gene mutation + GNA11 mutation → parathyroid infiltration: hemochromatosis + granulomatoses + metastases + amyloid deposits → low magnesium (<0.5 mmol/L) → PTH resistance + reduced PTH secretion → hypomagnesemia = frequent, correctable cause of functional hypoparathyroidism → correct before any other measures + cervical irradiation + Riedel surgery; PTH resistance - pseudohypoparathyroidism (PHP): elevated PTH + hypocalcemia + hyperphosphatemia → renal resistance to PTH by mutation of GNAS gene (Gsα protein) → PHP type 1a (Albright hereditary osteodystrophy - OHA): round facies + short stature + brachydactyly + obesity + mental retardation + subcutaneous ossifications + PHP type 1b: isolated renal resistance without OHA phenotype + PHP type 2: rare → workup: elevated PTH + low calcium + elevated phosphorus + urinary cAMP not increased after PTH injection → Mantovani 2011 - Endocrine Reviews: classification and management of PHP; vitamin D deficiency and vitamin D metabolism disorders: vitamin D deficiency (low 25-OHD): most frequent cause of mild to moderate hypocalcemia in the general population → inadequate dietary intake + insufficient sun exposure (northern latitude + covering clothing + photophobia) + malabsorption (celiac disease + Crohn's + intestinal resection + bariatric surgery) + liver failure (25-hydroxylation defect) → chronic renal failure (1α-hydroxylation) + vitamin-dependent rickets type 1 (VDDR1 - mutation of 1α-hydroxylase - CYP27B1) → very low calcitriol despite normal 25-OHD + vitamin-dependent rickets type 2 (VDDR2 - mutation of VDR - vitamin D receptor) → calcitriol resistance → very high calcitriol + clinical rickets → drugs inhibiting vitamin D metabolism : rifampicin + phenytoin + phenobarbital + carbamazepine (hepatic enzyme inducers → accelerated catabolism of 25-OHD); other causes to consider: chelation of blood calcium: acute pancreatitis (saponification of peripancreatic fats by free fatty acids → insoluble calcium-fatty acid complexes) + massive transfusions (citrate → chelates ionized calcium) + IV bisphosphonates + denosumab (after treatment of hypercalcemia) + excessive IV phosphate + acute fluorosis → severe hyperphosphatemia (CKD stage V) → calcium-phosphate precipitation → reduction of ionized calcium → tumor lysis syndrome: phosphorus + uric acid + potassium massively released → hyperphosphatemia → hypocalcemia → acute renal failure + severe hypoproteinemia: pseudo-hypocalcemia (low total calcuim + normal ionized calcium) → acute respiratory alkalosis (tetany without true total hypocalcemia + common in panic attacks)
- Clinical manifestations of hypocalcemia - «the 4 Es»: symptoms depend on ionized calcium level AND speed of onset - moderate chronic hypocalcemia may be asymptomatic, whereas an acute fall in calcium (post-surgery or tumor lysis) is much more symptomatic at the same blood calcium level; neuromuscular excitability (central manifestation): perioral paresthesias + tingling of extremities (fingers + toes) → muscle cramps → overt tetany: involuntary, painful contraction of hand muscles (midwife's hand - metacarpophalangeal flexion + interphalangeal extension) + feet (ballet foot - forced plantar extension) → laryngeal tetany (stridor + dyspnea + risk of asphyxia) → generalized tetany → convulsions (hypocalcemic epilepsy - grand mal + focal + absences); provoked clinical signs (sought on physical examination): Trousseau's sign: inflation of blood pressure cuff above PAS × 3 min → ischemia → midwife's hand → sensitivity 94 % + specificity 99 % for hypocalcemia (Tohme 1993 - Annals of Internal Medicine) → Chvostek's sign: percussion of facial nerve in front of tragus → ipsilateral contraction of facial muscles (lip + nostrils) → sensitivity 25-65 % (not very specific - 10-29 % false positives in normocalcemic general population) → Lust sign: percussion of peroneal nerve → dorsiflexion + eversion of foot; cardiovascular effects: QT interval prolongation (hypocalcemia → prolongation of ventricular repolarization) → opposite of hypercalcemia → risk of ventricular arrhythmias (torsades de pointes + VF) + heart failure (chronic hypocalcemic cardiomyopathy - reversible if calcium corrected) + arterial hypotension + AV block → ECG is mandatory if symptomatic or severe hypocalcemia; psychiatric and cognitive effects: anxiety + irritability + depression + confusion + memory disorders + dementia (untreated severe chronic hypocalcaemia) + calcifications of basal ganglia (basal ganglia) in chronic hypoparathyroidism (Fahr's syndrome - chorea + parkinsonism + dementia + epilepsy); ectodermal effects (long-term chronic hypoparathyroidism): posterior subcapsular cataract + skin dryness + brittle nails + hair loss + tooth enamel dysplasia (if deficient in childhood)
Biological diagnosis and management
| Aspect / intervention | Data, criteria and procedures | Key studies and recommendations |
|---|---|---|
| Diagnostic etiology PTH - 25-OHD - magnesium - phosphorus - calcitriol - cAMP - genetics - imaging |
Diagnostic algorithm - first step: correct calcium for albumin + assay ionized calcium if in doubt → exclude pseudo-hypocalcemia (hypoalbuminemia + alkalosis); 1st-line workup in the face of confirmed true hypocalcemia: intact PTH - key to etiological diagnosis: low or inadequately normal PTH (65 pg/mL) → non-parathyroid mechanism (vitamin D + PTH resistance + chelation + other) + phosphorus: high in hypoparathyroidism and CKD + low in vitamin D deficiency (high PTH → phosphaturia) + serum magnesium: mandatory → hypomagnesemia (<0.5 mmol/L) → functional hypoparathyroidism → magnesium correction → PTH correction → 25-OH-vitamin D (25-OHD): low (<25 nmol/L = severe deficiency + 25-50 nmol/L = insufficiency) → vitamin D deficiency → calcitriol (1,25-OH-vitamin D): low despite high PTH → 1α-hydroxylation deficiency (CKD + rickets type 1 CYP27B1) → high with low PTH and normal 25-OHD → rare (rickets type 2 or autonomous production) + creatinine + GFR → CKD (1α-hydroxylase defect + hyperphosphatemia) + alkaline phosphatases: very high → increased bone turnover → rickets + severe secondary hyperparathyroidism + 24h calciuria (or urinary Ca/Creat spot) → hypercalciuria in CaSR activating mutations + treated hypoparathyroidism (risk of nephro-calcinosis if supplementation too intensive) + CBC + ESR + CRP (sarcoidosis + hemochromatosis) + liver work-up (liver failure + metastases) + systematic ECG (prolonged QT - IV treatment threshold) ; 2nd-line work-up according to orientation: anti-parathyroid antibodies (autoimmune hypoparathyroidism) + genetics: GNAS (PHP) + CaSR activator (Pollak 1994 - Nature Genetics) + AIRE (APS-1) + GNA11 + CYP27B1 (VDDR1) + VDR (VDDR2) + 22q11.2 (DiGeorge - FISH or CGH-array) + parathyroid scintigraphy + cervical CT (if suspicion of remaining nonpalpated functional ectopic parathyroids) + ferritin + transferrin saturation (hemochromatosis) + abdominal CT if sarcoidosis suspected + Ellsworth-Howard test (PTH injection → urinary cAMP not increased in PHPs) → today replaced by GNAS genetics + ophthalmological workup: fundus + slit lamp → posterior subcapsular cataract (chronic hypoparathyroidism) + brain scan if neurological symptoms: calcifications of basal ganglia (Fahr syndrome) → in untreated or inadequately treated hypoparathyroidism → no MRI (calcifications are not visible on MRI but on CT); classification of hypocalcemia severity: mild : corrected calcium 1.90-2.10 mmol/L → often asymptomatic → oral treatment + follow-up → moderate: corrected calcium 1.75-1.90 mmol/L → paresthesias + cramps → intensified oral treatment → severe: <1.75 mmol/L or severe symptoms (tetany + convulsions + prolonged QTc + arrhythmia) → emergency → IV calcium | Interpretation of the biological profile according to etiology: hypoparathyroidism: Ca↓ + PTH↓ or inadequate + PO₄↑ + normal/low Mg + normal 25-OHD + calcitriol ↓ + high calciuria → vitamin D deficiency: Ca↓ slightly + PTH↑ + PO₄↓ + 25-OHD↓↓ + variable calcitriol + PAL↑ + calciuria↓ → CKD: Ca↓ + PTH↑↑ (secondary) + PO₄↑ + 25-OHD↓ + calcitriol↓ + creatinine↑ → PHP: Ca↓ + PTH↑↑ + PO₄↑ + normal 25-OHD + calcitriol↓ + non-stimulable urinary cAMP → activating CaSR mutation: Ca↓ + maladaptive (low) PTH + normal calciuria↑↑ + PO₄ → Bilezikian 2016 - Journal of Bone and Mineral Research : international guidelines for hypoparathyroidism → consensus of 73 experts → therapeutic targets + indications for recombinant PTH + Mannstadt 2017 - Nature Reviews Disease Primers: comprehensive review of hypoparathyroidism → epidemiology + mechanisms + treatment |
| Treatment of acute hypocalcemia and tetany IV calcium gluconate - calcium chloride - continuous infusion - calcitriol - magnesium - ECG monitoring |
Treatment of acute or severe symptomatic hypocalcemia (calcium <1.75 mmol/L or neuromuscular signs): intravenous calcium - emergency treatment: calcium gluconate 10 % (standard solution): 1-2 ampoules of 10 mL (each containing 93 mg = 2.3 mmol elemental calcium) → dilute in 50-100 mL saline or G5 % → infuse in 10-20 min → never inject as a direct bolus (risk of severe bradycardia + asystole) → effect on QT in 15-30 min → peripheral or central route (calcium gluconate is less irritating than calcium chloride → peripheral IV preferred) → calcium chloride 10 %: contains 3 times more elemental calcium (272 mg / 10 mL) → reserved for central venous access or extreme emergencies → very irritating to peripheral veins → risk of necrosis if extravasated → maintenance infusion if persistent profound hypocalcemia: calcium gluconate 10 %: 8-12 ampoules in 1 L saline → flow rate: 50-100 mL/h → adjust according to ionized calcemia (target 1.15-1.25 mmol/L) → monitor calcemia every 2-4h + continuous ECG + diuresis → extravasation of IV calcium: risk of skin necrosis → use central line or large vein → do not mix calcium with bicarbonate (precipitation); magnesium correction if hypoMg: magnesium sulfate 1-2 g IV over 10-15 min + infusion maintenance → essential before PTH can respond normally → without magnesium correction → calcium supplementation will be insufficient → systematically check magnesium in any hypocalcemia; emergency calcitriol initiation (suspected hypoparathyroidism): calcitriol (Rocaltrol) 0.25-0.5 µg 2×/d orally → rapid onset of action (12-24h for onset of intestinal effect) → essential in hypoparathyroidism (absence of endogenous renal calcitriol production under PTH) → do not wait for full correction to initiate → objectives: corrected calcium maintained between 2.00 and 2.25 mmol/L (do not aim for full normality → risk of nephro-calcinosis and lithiasis if Ca × PO₄ high) → monitor calciuria (target <7.5 mmol/24h); treatment of true hypocalcemic tetany as an emergency: IV calcium according to above scheme + continuous ECG monitoring + reassure patient + treat triggering cause + if laryngeal tetany: intubation if severe stridor + emergency call + immediate IV calcium gluconate; pseudo-tetany by hyperventilation (acute respiratory alkalosis): bag breathing (rebreathing CO₂) → correction of alkalosis → ionized calcium normalizes → no IV calcium → anxiolytic if panic attack + treatment of underlying anxiety | Data on IV treatment of acute hypocalcemia: Cooper 2012 - New England Journal of Medicine (review): calcium gluconate IV = gold standard treatment of acute symptomatic hypocalcemia → 1-2 g IV in 10-20 min → followed by maintenance infusion if persistent ionized calcium 500 ms + ionized calcium <1.0 mmol/L → immediate IV treatment → correction → QTc shortens in 15-30 min → Zaloga 1992 - Critical Care Medicine: hypocalcemia in intensive care → frequency 15-20 % of ICU patients + poor prognostic factor + Moe 2008 - Kidney International: treatment of hypocalcemia in CKD → calcitriol + oral calcium + phosphorus control → KDIGO 2017 guidelines: target Ca × PO₄ ≤ 4.4 mmol²/L² to reduce vascular calcifications; post-thyroidectomy - prediction and prevention: Bove 2011 - Surgery: PTH measured at H4 post-thyroidectomy → PTH <10 pg/mL → predictive of symptomatic hypocalcemia in 85 % of cases → systematic initiation of oral calcium + calcitriol if PTH <10 pg/mL at H4 → Edafe 2014 - British Journal of Surgery: meta-analysis → early PTH (H1-H6) → best predictor of post-thyroidectomy hypocalcemia → sensitivity 82 % + specificity 86 % |
| Chronic treatment of hypoparathyroidism Oral calcium - calcitriol - alphacalcidol - recombinant PTH - natpara - nephro-calcinosis - follow-up - targets |
Conventional treatment of chronic hypoparathyroidism: oral calcium carbonate or calcium citrate: dose: 1,000-2,000 mg/d of elemental calcium in 2-3 doses + calcium carbonate: taken with meals (requires gastric acidity for dissolution - less effective in patients on PPIs) → calcium citrate: can be taken outside meals + more effective in patients on PPIs or with achlorhydria + elements to avoid in combination: phytates (wheat bran + legumes in excess) + oxalates (spinach + rhubarb) → reduce calcium absorption; calcitriol (1,25-dihydroxy-vitamin D3 - Rocaltrol): reference treatment in hypoparathyroidism → replaces renal production of calcitriol normally stimulated by PTH → usual dose: 0.25-2 µg/d in 2 doses → titration according to calcemia and calciuria → survival with ACEI/ARA-2: do not withdraw calcitriol abruptly → regression → hypocalcemia → alphacalcidol (1α-hydroxyvitamin D3 - One-Alpha): pro-drug → hydroxylated to calcitriol by the liver → longer half-life → 1-4 µg/d → alternative to calcitriol → therapeutic targets (Bilezikian 2016 - Journal of Bone and Mineral Research - International Guidelines): corrected total serum calcium: 2.00-2.25 mmol/L (lower limit of normal - do not aim for 2.35-2.60 mmol/L → risk of nephro-calcinosis and renal lithiasis as PTH absent → no renal tubular reabsorption of calcium → relative hypercalciuria) + 24h calciuria: <7.5 mmol/d (female) + <8.5 mmol/d (male) → if hypercalciuria: reduce oral calcium + reduce calcitriol → consider thiazide diuretic (HCTZ 25 mg/d → increases tubular calcium reabsorption) + serum phosphorus: normal or slightly elevated (acceptable in absence of PTH) + magnesium: within norms → monitor and supplement if low; follow-up of treated chronic hypoparathyroidism: calcium + phosphorus + magnesium + creatinine + 24h calciuria → every 3 months initially → then every 6 months if stable + annual renal ultrasound (nephro-calcinosis + lithiasis) → fundus (cataract) → DXA bone densitometry (absence of PTH → less bone resorption → bone density often paradoxically high - Bilezikian 2016) + cardiovascular workup (QTc) + quality of life (chronic hypoparathyroidism significantly impairs quality of life - Underbjerg 2015 - European Journal of Endocrinology) ; recombinant parathyroid hormone - rhPTH 1-84 (Natpara) : hormone replacement therapy for hypoparathyroidism → daily SC injection (50-100 µg/d) → Bilezikian 2016 - New England Journal of Medicine (REPLACE study): RCT n=134 → rhPTH 1-84 → reduction of oral calcium by 50 % + reduction of calcitriol by 50 % + normalization of calcium in 53 % vs 2 % placebo → adverse effects: hypercalcemia if dose too high + CAUTION: osteosarcoma risk signals in rats in preclinical studies (prolonged exposure duration at high doses) → contraindicated if bone Paget + bone radiotherapy + unexplained elevation of alkaline phosphatases → recommended for hypoparathyroidism difficult to control despite optimal conventional treatment (persistent hypocalcemia or severe hypercalciuria on calcitriol) → approval: FDA (2015) + EMA (2017) → limited availability in Canada (compassionate use + awaiting full Health Canada approval) → alternative in development: TransCon PTH (sustained-release PTH) → phase III studies underway | Key data on chronic hypoparathyroidism treatment: Bilezikian 2016 - Journal of Bone and Mineral Research: international hypoparathyroidism guidelines + 73 experts + Bilezikian 2016 - NEJM (REPLACE study): rhPTH 1-84 → reduced oral calcium dependence + calcium normalization + improved quality of life → founder result → Underbjerg 2015 - European Journal of Endocrinology: n=688 hypoparathyroid patients + comparison with general population → significantly impaired quality of life (physical + mental + fatigue) → more frequent anxiety + depression + Edafe 2014 - British Journal of Surgery: meta-analysis 52 studies → PTH at H4 post-thyroidectomy = best predictor of post-operative hypocalcaemia → guides early supplementation → reduced hospital admissions + Mannstadt 2017 - Nature Reviews Disease Primers: epidemiology + prevalence of chronic post-surgical hypoparathyroidism in Europe: 22/100,000 person-years + estimated prevalence 37,000 people + Canada: estimated prevalence 3,000-5,000 cases → conventional treatment unsatisfactory in 20-30 % of patients (persistent hypocalcemia or hypercalciuria) + Sanders 2019 - Endocrine: thiazide (chlorthalidone 25 mg/d) in hypoparathyroidism with hypercalciuria → reduction of calciuria by 25-30 % → reduced risk of nephro-calcinosis |
| Special populations and situations Post-thyroidectomy - infant - CKD - rickets - pregnancy - nephro-calcinosis - DiGeorge - APS-1 |
Post-thyroidectomy hypocalcemia - prevention and management: monitoring: PTH at H1-H4 postoperatively + calcium at H6 and H24 → if PTH <10 pg/mL at H4 → systematic initiation of oral calcium (1,000-2,000 mg/d) + calcitriol 0.25 µg 2×/d → Bove 2011 - Surgery: systematic protocol → reduction in hospitalizations for symptomatic hypocalcemia → IV calcium if symptoms or calcium 6 months) → chronic treatment according to guidelines; neonatal hypocalcemia: early neonatal hypocalcemia (D1-J3): prematurity + IUGR + son of diabetic mother + neonatal asphyxia + hypomagnesemia → calcium gluconate IV 200 mg/kg/d → late neonatal hypocalcemia (D5-J7): phosphorus-rich milks + hyperphosphatemia → transient hypoparathyroidism + maternal deficiency rickets → native vitamin D + oral calcium + genetic diagnosis if persistent → DiGeorge (22q11.2): immune workup (T lymphocytes) + echocardiography + ENT → chronic calcium + calcitriol if permanent hypoparathyroidism; hypocalcemia and CKD - secondary and tertiary hyperparathyroidism: CKD → 1α-hydroxylase defect → low calcitriol + phosphorus retention → hyperphosphatemia → hypocalcemia → secondarily elevated PTH → KDIGO 2017 goals: normal phosphorus + normal calcium + PTH 2-9× upper limit of normal (moderately elevated PTH needed to maintain bone remodeling in CKD) → treatment: IV or oral calcitriol + sevelamer (phosphorus binder) + cinacalcet (calcimimetic if very high PTH) → tertiary hyperparathyroidism (parathyroid autonomization after transplantation or prolonged CKD) → hypercalcemia + very high PTH → subtotal or total parathyroidectomy with autotransplantation → then post-operative hypocalcemia (hungry bone syndrome often intense); carential rickets - management: vitamin D3 (cholecalciferol) 2,000-4,000 IU/d × 3 months + calcium 500 mg/d + then vitamin D3 400-1,000 IU/d maintenance → Holick 2011 - Journal of Clinical Endocrinology and Metabolism: vitamin D guidelines → defined deficiency <50 nmol/L (25-OHD) → recommended treatment + therapeutic target: 25-OHD ≥75 nmol/L → Munns 2016 - Journal of Clinical Endocrinology and Metabolism: global consensus on prevention and treatment of deficiency rickets → vitamin D + calcium + maternal supplementation during pregnancy and lactation + pregnancy and hypocalcemia: frequent maternal vitamin D deficiency → recommended supplementation: vitamin D3 600-2,000 IU/d throughout pregnancy → ACOG 2021 + Hypoparathyroidism and pregnancy: calcium + calcitriol requirements increase in 3rd trimester + breastfeeding → requirements further increased → adjust calcitriol doses + monitor blood calcium levels monthly + risk of neonatal hypocalcemia if hypoparathyroid mother insufficiently treated | Vitamin D supplementation recommendations in Canada: Osteoporosis Canada 2022 + SCP 2023: adults <50 years: 400-1,000 IU/d vitamin D3 maintenance → adults ≥50 years: 800-2,000 IU/d → pregnancy + breastfeeding: 400-2,000 IU/d → breastfed infants: 400 IU/d from birth → at-risk populations (dark skin + covering clothing + low sun exposure + obesity + malabsorption): 800-2,000 IU/d → correction of documented deficiency (25-OHD <50 nmol/L): vitamin D3 50,000 IU/week × 8-12 weeks (prescribing physician) → then maintenance 800-2,000 IU/d → Holick 2011 - JCEM: treatment of vitamin D deficiency → 50,000 IU/week vitamin D2 or D3 × 8 weeks → then 1,500-2,000 IU/d → Munns 2016 - JCEM: international consensus rickets → systematic vitamin D + calcium in all countries → in areas with low sunshine + diet low in vitamin D → universal supplementation of infants + prevention in high-risk populations (immigrants from tropical countries + veiled women + elderly people in institutions): public health priority → Rosen 2012 - NEJM: comprehensive review of vitamin D + randomized studies: no additional cardiovascular benefit demonstrated at high doses (VITAL trial Manson 2019 - NEJM) but bone and muscle benefit recognized at physiological doses |
Overt tetany with midwife's hand, generalized painful cramps, laryngeal stridor or convulsions → severe symptomatic hypocalcemia → call 911 → calcium gluconate 10 % IV (1-2 g in 10-20 min) → continuous ECG → ionized calcium monitoring → laryngeal tetany: risk of asphyxia → prepare for intubation → never inject calcium as a direct bolus.
Postoperative total thyroidectomy or parathyroidectomy patient with perioral paresthesia + tingling of extremities + positive Chvostek's sign → early post-surgical hypocalcemia → surgical or medical emergencies → oral calcium + calcitriol if moderate → IV calcium if severe + PTH at H4 post-op.
QTc prolongation on ECG (QTc >500 ms) + confirmed hypocalcemia → risk of malignant ventricular arrhythmias (torsades de pointes + ventricular fibrillation) → emergency hospitalization → continuous cardiac monitoring → IV calcium gluconate → correction of any aggravating causes (hypokalemia + hypomagnesemia + QT-prolonging drugs).
Infants or children with stridor, tetany or hypocalcemic convulsions → pediatric emergencies → pediatric IV calcium gluconate (50-100 mg/kg in 10 min) + ECG + monitoring → urgent etiological workup (DiGeorge 22q11.2 to be excluded) + neonatology or specialized pediatrics.
Consult at Clinique Omicron
Les médecins de Clinique Omicron évaluent les hypocalcémies découvertes en ambulatoire, prescrivent et interprètent le bilan étiologique complet (PTH, 25-OHD, magnésium, phosphore, calciurie), initient la supplémentation en vitamine D et en calcium selon les recommandations en vigueur, et orientent vers l'endocrinologue si une hypoparathyroïdie chronique ou une résistance à la PTH est suspectée. Des consultations sont disponibles dans plusieurs points de service au Québec et en télémédecine. Pour prendre rendez-vous, choisissez votre service en ligne.
The contents of this page are provided for information purposes only and do not replace medical advice. Symptomatic hypocalcemia (tetany, convulsions, arrhythmia) is a medical emergency requiring immediate hospital evaluation.
Omicron Clinic
Need to consult a doctor?
En clinique ou en télémédecine, partout au Québec.
Reçus pour assurances. Téléconsultation 7 j/7. Sans médecin de famille requis.